# Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)

> **NCT03224819** · EARLY_PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 46 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Emerfetamab

## Key facts

- **NCT ID:** NCT03224819
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-07
- **Primary completion:** 2020-12-28
- **Final completion:** 2020-12-28
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Priortization of other Programs
- **Last updated:** 2023-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03224819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03224819, "Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03224819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*